NCOA3 and breast carcinoma: Therefore, we developed SI-2, a small-molecule inhibitor of SRC-3, as a novel breast cancer therapeutic agent, and SI-2 treatment suppressed the growth of MDA-MB-468 cells in immunodeficient mice by inhibiting SRC-3-mediated proliferation [11].